These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25407815)

  • 1. Murine model for non-invasive imaging to detect and monitor ovarian cancer recurrence.
    Sumi NJ; Lima E; Pizzonia J; Orton SP; Craveiro V; Joo W; Holmberg JC; Gurrea M; Yang-Hartwich Y; Alvero A; Mor G
    J Vis Exp; 2014 Nov; (93):e51815. PubMed ID: 25407815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenograft and transgenic mouse models of epithelial ovarian cancer and non-invasive imaging modalities to monitor ovarian tumor growth in situ: applications in evaluating novel therapeutic agents.
    Connolly DC; Hensley HH
    Curr Protoc Pharmacol; 2009 Jun; Chapter 14():Unit14.12. PubMed ID: 22294392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of outcomes of secondary debulking surgery for recurrent epithelial ovarian cancer with favorable prognostic factors.
    Nasu K; Kai K; Hirakawa T; Nishida M; Matsumoto H; Kawano Y; Narahara H
    J Obstet Gynaecol Res; 2014 Mar; 40(3):791-6. PubMed ID: 24245582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer.
    Frederick PJ; Ramirez PT; McQuinn L; Milam MR; Weber DM; Coleman RL; Gershenson DM; Landen CN
    Int J Gynecol Cancer; 2011 Jul; 21(5):831-6. PubMed ID: 21613957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.
    Ricci F; Bizzaro F; Cesca M; Guffanti F; Ganzinelli M; Decio A; Ghilardi C; Perego P; Fruscio R; Buda A; Milani R; Ostano P; Chiorino G; Bani MR; Damia G; Giavazzi R
    Cancer Res; 2014 Dec; 74(23):6980-90. PubMed ID: 25304260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paraaortic node recurrence 25 years after removal of epithelial ovarian carcinoma.
    Otsuka I; Shoji K
    J Obstet Gynaecol Res; 2016 Nov; 42(11):1609-1612. PubMed ID: 27641229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast recruitment as a tool for ovarian cancer detection and targeted therapy.
    Oren R; Addadi Y; Narunsky Haziza L; Dafni H; Rotkopf R; Meir G; Fishman A; Neeman M
    Int J Cancer; 2016 Oct; 139(8):1788-98. PubMed ID: 27242346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Specific folic-acid targeted photosensitizer. The first step toward intraperitoneal photodynamic therapy for epithelial ovarian cancer].
    Azaïs H; Frochot C; Grabarz A; Khodja Bach S; Colombeau L; Delhem N; Mordon S; Collinet P
    Gynecol Obstet Fertil Senol; 2017 Apr; 45(4):190-196. PubMed ID: 28359805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
    Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
    Heo EJ; Cho YJ; Cho WC; Hong JE; Jeon HK; Oh DY; Choi YL; Song SY; Choi JJ; Bae DS; Lee YY; Choi CH; Kim TJ; Park WY; Kim BG; Lee JW
    Cancer Res Treat; 2017 Oct; 49(4):915-926. PubMed ID: 28052650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
    Hall TR; Dizon DS
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):262-8. PubMed ID: 27166608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.
    Fagotti A; Petrillo M; Costantini B; Fanfani F; Gallotta V; Chiantera V; Turco LC; Bottoni C; Scambia G
    Gynecol Oncol; 2014 Feb; 132(2):303-6. PubMed ID: 24378877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing treatment in recurrent epithelial ovarian cancer.
    Corrado G; Salutari V; Palluzzi E; Distefano MG; Scambia G; Ferrandina G
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1147-1158. PubMed ID: 29086618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of chemotherapy in epithelial ovarian cancer.
    Markman M
    Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience.
    Tempfer CB; Celik I; Solass W; Buerkle B; Pabst UG; Zieren J; Strumberg D; Reymond MA
    Gynecol Oncol; 2014 Feb; 132(2):307-11. PubMed ID: 24275155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.